Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

2.1 Lorlatinib (Lorviqua) is indicated for the 'treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) previously not treated with an ALK inhibitor'.

2.2 Lorlatinib is also indicated for previously treated ALK‑positive advanced NSCLC (see NICE's technology appraisal guidance on lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer).

2.3 The dosage schedule is available in the summary of product characteristics for lorlatinib.

2.4 The list price of lorlatinib 30x100 mg and 90x25 mg tablets is £5,283 (excluding VAT; BNF online accessed March 2023).

2.5 The company has a commercial arrangement. This makes lorlatinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.